{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T08:27:58Z","timestamp":1780388878707,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,8,13]]},"DOI":"10.7759\/cureus.27965","type":"journal-article","created":{"date-parts":[[2022,8,13]],"date-time":"2022-08-13T14:15:43Z","timestamp":1660400143000},"source":"Crossref","is-referenced-by-count":4,"title":["A Review of Central Serous Chorioretinopathy: Clinical Presentation and Management"],"prefix":"10.7759","author":[{"given":"Jerin","family":"Varghese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipanshu","family":"Kesharwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreya","family":"Parashar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prerna","family":"Agrawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.preteyeres.2015.05.003","article-title":"Central serous chorioretinopathy: recent findings and new physiopathology hypothesis","volume":"48","author":"Daruich A","year":"2015","unstructured":"Daruich A, Matet A, Dirani A, et al.. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015, 48:82-118. 10.1016\/j.preteyeres.2015.05.003","journal-title":"Prog Retin Eye Res"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1111\/aos.12392","article-title":"The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy","volume":"92","author":"Breukink MB","year":"2014","unstructured":"Breukink MB, den Hollander AI, Keunen JE, Boon CJ, Hoyng CB. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy. Acta Ophthalmol. 2014, 92:e488-90. 10.1111\/aos.12392","journal-title":"Acta Ophthalmol"},{"key":"ref3","article-title":"Type A behavior and central serous chorioretinopathy","volume":"84","author":"Yannuzzi LA","year":"1986","unstructured":"Yannuzzi LA. Type A behavior and central serous chorioretinopathy. Trans Am Ophthalmol Soc. 1986, 84:799-845.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref4","article-title":"[Hemorrhagic detachment of the pigment epithelium (hematoma under the retinal pigment epithelium)--relationship with macula lutea hemorrhage and central serous choroidopathy (Masuda's type)]","volume":"13","author":"Tsukahara I","year":"1971","unstructured":"Tsukahara I. [Hemorrhagic detachment of the pigment epithelium (hematoma under the retinal pigment epithelium)--relationship with macula lutea hemorrhage and central serous choroidopathy (Masuda's type)]. Ganka. 1971, 13:832-6.","journal-title":"Ganka"},{"key":"ref5","article-title":"Epith\u00e9liopathie r\u00e9tinienne diffuse et chorior\u00e9tinopathie s\u00e9reuse centrale [Diffuse retinal epitheliopathy and central serous chorioretinopathy]","volume":"6","author":"Cohen D","year":"1983","unstructured":"Cohen D, Gaudric A, Coscas G, Quentel G, Binaghi M. Epith\u00e9liopathie r\u00e9tinienne diffuse et chorior\u00e9tinopathie s\u00e9reuse centrale [Diffuse retinal epitheliopathy and central serous chorioretinopathy]. J Fr Ophtalmol. 1983, 6:339-49.","journal-title":"J Fr Ophtalmol"},{"key":"ref6","article-title":"Central serous retinopathy dynamics of subretinal fluid","volume":"9","author":"Shimizu K","year":"1971","unstructured":"Shimizu K, Tobari I. Central serous retinopathy dynamics of subretinal fluid. Mod Probl Ophthalmol. 1971, 9:152-7.","journal-title":"Mod Probl Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(99)00272-x","article-title":"Evaluation of central serous chorioretinopathy with optical coherence tomography","volume":"129","author":"Iida T","year":"2000","unstructured":"Iida T, Hagimura N, Sato T, Kishi S. Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol. 2000, 129:16-20. 10.1016\/s0002-9394(99)00272-x","journal-title":"Am J Ophthalmol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1016\/s0002-9394(14)70531-8","article-title":"Choroidal capillary and venous congestion in central serous chorioretinopathy","volume":"121","author":"Pr\u00fcnte C","year":"1996","unstructured":"Pr\u00fcnte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. Am J Ophthalmol. 1996, 121:26-34. 10.1016\/s0002-9394(14)70531-8","journal-title":"Am J Ophthalmol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9394(67)90027-X","article-title":"Pathogenesis of disciform detachment of the neuroepithelium: II. Idiopathic central serous choroidopathy","volume":"63","author":"Donald J","year":"1967","unstructured":"Donald J, Gass M. Pathogenesis of disciform detachment of the neuroepithelium: II. Idiopathic central serous choroidopathy. Am J Ophthalmol. 1967, 63:587\/15-615\/43. 10.1016\/0002-9394(67)90027-X","journal-title":"Am J Ophthalmol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.72.11.829","article-title":"Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy","volume":"72","author":"Ficker L","year":"1988","unstructured":"Ficker L, Vafidis G, While A, Leaver P. Long-term follow-up of a prospective trial of argon laser photocoagulation in the treatment of central serous retinopathy. Br J Ophthalmol. 1988, 72:829-34. 10.1136\/bjo.72.11.829","journal-title":"Br J Ophthalmol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10040558","article-title":"Central serous chorioretinopathy and blood serotonin concentrations","volume":"10","author":"Kimura T","year":"2021","unstructured":"Kimura T, Araki T, Komuku Y, Iwami H, Gomi F. Central serous chorioretinopathy and blood serotonin concentrations. J Clin Med. 2021, 10:558. 10.3390\/jcm10040558","journal-title":"J Clin Med"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000002108","article-title":"Photodynamic therapy for symptomatic subfoveal retinal pigment epithelial detachment in central serous chorioretinopathy: outcomes and prognostic factors","volume":"39","author":"Hwang S","year":"2019","unstructured":"Hwang S, Kang SW, Kim SJ, Jang JW, Kim KT. Photodynamic therapy for symptomatic subfoveal retinal pigment epithelial detachment in central serous chorioretinopathy: outcomes and prognostic factors. Retina. 2019, 39:1117-24. 10.1097\/IAE.0000000000002108","journal-title":"Retina"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm9113429","article-title":"Short term presence of subretinal fluid in central serous chorioretinopathy affects retinal thickness and function","volume":"9","author":"Gaw\u0119cki M","year":"2020","unstructured":"Gaw\u0119cki M, Jaszczuk A, Grzybowski A. Short term presence of subretinal fluid in central serous chorioretinopathy affects retinal thickness and function. J Clin Med. 2020, 9:3429. 10.3390\/jcm9113429","journal-title":"J Clin Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0420.2007.00889.x","article-title":"Central serous chorioretinopathy","volume":"86","author":"Wang M","year":"2008","unstructured":"Wang M, Munch IC, Hasler PW, Pr\u00fcnte C, Larsen M. Central serous chorioretinopathy. Acta Ophthalmol. 2008, 86:126-45. 10.1111\/j.1600-0420.2007.00889.x","journal-title":"Acta Ophthalmol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1186\/s40942-018-0137-8","article-title":"Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature","volume":"4","author":"Chatziralli I","year":"2018","unstructured":"Chatziralli I, Vlachodimitropoulou A, Daoula C, Vrettou C, Galani E, Theodossiadis G, Theodossiadis P. Eplerenone in the treatment of central serous chorioretinopathy: a review of the literature. Int J Retina Vitreous. 2018, 4:33. 10.1186\/s40942-018-0137-8","journal-title":"Int J Retina Vitreous"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/6913980","article-title":"Detection of silent type I choroidal neovascular membrane in chronic central serous chorioretinopathy using en face swept-source optical coherence tomography angiography","volume":"2017","author":"Moussa M","year":"2017","unstructured":"Moussa M, Leila M, Khalid H, Lolah M. Detection of silent type I choroidal neovascular membrane in chronic central serous chorioretinopathy using en face swept-source optical coherence tomography angiography. J Ophthalmol. 2017, 2017:6913980. 10.1155\/2017\/6913980","journal-title":"J Ophthalmol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1155\/2017\/3048013","article-title":"Correlation between choroidal neovascularization shown by OCT angiography and choroidal thickness in patients with chronic central serous chorioretinopathy","volume":"2017","author":"Go\u0142\u0119biewska J","year":"2017","unstructured":"Go\u0142\u0119biewska J, Brydak-Godowska J, Moneta-Wielgo\u015b J, Turczy\u0144ska M, K\u0119cik D, Hautz W. Correlation between choroidal neovascularization shown by OCT angiography and choroidal thickness in patients with chronic central serous chorioretinopathy. J Ophthalmol. 2017, 2017:3048013. 10.1155\/2017\/3048013","journal-title":"J Ophthalmol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.survophthal.2012.07.004","article-title":"Central serous chorioretinopathy: update on pathophysiology and treatment","volume":"58","author":"Nicholson B","year":"2013","unstructured":"Nicholson B, Noble J, Forooghian F, Meyerle C. Central serous chorioretinopathy: update on pathophysiology and treatment. Surv Ophthalmol. 2013, 58:103-26. 10.1016\/j.survophthal.2012.07.004","journal-title":"Surv Ophthalmol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.2147\/OPTH.S242926","article-title":"Risk of recurrence and transition to chronic disease in acute central serous chorioretinopathy","volume":"14","author":"Mohabati D","year":"2020","unstructured":"Mohabati D, Boon CJ, Yzer S. Risk of recurrence and transition to chronic disease in acute central serous chorioretinopathy. Clin Ophthalmol. 2020, 14:1165-75. 10.2147\/OPTH.S242926","journal-title":"Clin Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.3390\/ph14020105","article-title":"The role of imaging in planning treatment for central serous chorioretinopathy","volume":"14","author":"Da Pozzo S","year":"2021","unstructured":"Da Pozzo S, Iacono P, Arrigo A, Battaglia Parodi M. The role of imaging in planning treatment for central serous chorioretinopathy. Pharmaceuticals (Basel). 2021, 14:105. 10.3390\/ph14020105","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1038\/eye.2017.293","article-title":"Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up","volume":"32","author":"Arsan A","year":"2018","unstructured":"Arsan A, Kanar HS, Sonmez A. Visual outcomes and anatomic changes after sub-threshold micropulse yellow laser (577-nm) treatment for chronic central serous chorioretinopathy: long-term follow-up. Eye (Lond). 2018, 32:726-33. 10.1038\/eye.2017.293","journal-title":"Eye (Lond)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/bjo.87.12.1453","article-title":"Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level","volume":"87","author":"Chan WM","year":"2003","unstructured":"Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol. 2003, 87:1453-8. 10.1136\/bjo.87.12.1453","journal-title":"Br J Ophthalmol"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2008.04.014","article-title":"Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial","volume":"115","author":"Chan WM","year":"2008","unstructured":"Chan WM, Lai TY, Lai RY, Liu DT, Lam DS. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial. Ophthalmology. 2008, 115:1756-65. 10.1016\/j.ophtha.2008.04.014","journal-title":"Ophthalmology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2014.5312","article-title":"A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial","volume":"133","author":"Zhao M","year":"2015","unstructured":"Zhao M, Zhang F, Chen Y, et al.. A 50% vs 30% dose of verteporfin (photodynamic therapy) for acute central serous chorioretinopathy: one-year results of a randomized clinical trial. JAMA Ophthalmol. 2015, 133:333-40. 10.1001\/jamaophthalmol.2014.5312","journal-title":"JAMA Ophthalmol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0000000000001138","article-title":"Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy","volume":"37","author":"Cheng CK","year":"2017","unstructured":"Cheng CK, Chang CK, Peng CH. Comparison of photodynamic therapy using half-dose of verteporfin or half-fluence of laser light for the treatment of chronic central serous chorioretinopathy. Retina. 2017, 37:325-33. 10.1097\/IAE.0000000000001138","journal-title":"Retina"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1159\/000490773","article-title":"Long-term outcomes of full-fluence and half-fluence photodynamic therapy for chronic central serous chorioretinopathy","volume":"241","author":"Son BK","year":"2019","unstructured":"Son BK, Kim K, Kim ES, Yu SY. Long-term outcomes of full-fluence and half-fluence photodynamic therapy for chronic central serous chorioretinopathy. Ophthalmologica. 2019, 241:105-15. 10.1159\/000490773","journal-title":"Ophthalmologica"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.1097\/IAE.0b013e318242b9ab","article-title":"Half-fluence photodynamic therapy in acute central serous chorioretinopathy","volume":"32","author":"Smretschnig E","year":"2012","unstructured":"Smretschnig E, Ansari-Shahrezaei S, Moussa S, Glittenberg C, Krebs I, Binder S. Half-fluence photodynamic therapy in acute central serous chorioretinopathy. Retina. 2012, 32:2014-9. 10.1097\/IAE.0b013e318242b9ab","journal-title":"Retina"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.4274\/tjo.galenos.2022.96461","article-title":"Half-fluence photodynamic therapy for central serous chorioretinopathy in a patient receiving corticosteroids for Beh\u00e7et's uveitis","volume":"52","author":"\u00d6zdemir HB","year":"2022","unstructured":"\u00d6zdemir HB, Zhoroeva N, \u00c7akar \u00d6zdal P, \u00d6zdek \u015e. Half-fluence photodynamic therapy for central serous chorioretinopathy in a patient receiving corticosteroids for Beh\u00e7et's uveitis. Turk J Ophthalmol. 2022, 52:142-6. 10.4274\/tjo.galenos.2022.96461","journal-title":"Turk J Ophthalmol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1080\/08820538.2017.1416414","article-title":"Half-fluence photodynamic therapy for chronic central serous chorioretinopathy: predisposing factors for visual acuity outcomes","volume":"33","author":"Matu\u0161kov\u00e1 V","year":"2018","unstructured":"Matu\u0161kov\u00e1 V, Vyslou\u017eilov\u00e1 D, Uher M. Half-fluence photodynamic therapy for chronic central serous chorioretinopathy: predisposing factors for visual acuity outcomes. Semin Ophthalmol. 2018, 33:690-9. 10.1080\/08820538.2017.1416414","journal-title":"Semin Ophthalmol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1007\/s10792-016-0286-4","article-title":"Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment","volume":"37","author":"Arf S","year":"2017","unstructured":"Arf S, Hocaoglu M, Sayman Muslubas I, Karacorlu M. Efficacy of reduced-fluence photodynamic therapy for central serous chorioretinopathy associated with combined serous retinal detachment and fovea-involving pigment epithelial detachment. Int Ophthalmol. 2017, 37:483-9. 10.1007\/s10792-016-0286-4","journal-title":"Int Ophthalmol"},{"key":"ref31","article-title":"Central serous chorioretinopathy (CSCR)","volume":"35","author":"Das S","year":"2017","unstructured":"Das S, Das D. Central serous chorioretinopathy (CSCR). Sci J Med Vis Res Foun. 2017, 35:10-20.","journal-title":"Sci J Med Vis Res Foun"},{"key":"ref32","article-title":"Long-term outcome of half-dose verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (an American Ophthalmological Society Thesis)","volume":"113","author":"Lai TY","year":"2015","unstructured":"Lai TY, Wong RL, Chan WM. Long-term outcome of half-dose verteporfin photodynamic therapy for the treatment of central serous chorioretinopathy (an American Ophthalmological Society Thesis). Trans Am Ophthalmol Soc. 2015, 113:T8.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1038\/s41433-019-0381-7","article-title":"Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options","volume":"33","author":"Sartini F","year":"2019","unstructured":"Sartini F, Figus M, Nardi M, Casini G, Posarelli C. Non-resolving, recurrent and chronic central serous chorioretinopathy: available treatment options. Eye (Lond). 2019, 33:1035-43. 10.1038\/s41433-019-0381-7","journal-title":"Eye (Lond)"},{"key":"ref34","article-title":"The effect of intravitreal bevacizumab on central serous chorioretinopathy","volume":"7","author":"Maleki A","year":"2018","unstructured":"Maleki A, Nezamdust Z, Salari A, et al.. The effect of intravitreal bevacizumab on central serous chorioretinopathy. Med Hypothesis Discov Innov Ophthalmol. 2018, 7:176-82.","journal-title":"Med Hypothesis Discov Innov Ophthalmol"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1159\/000519234","article-title":"Central serous chorioretinopathy: morphological and functional outcome after subthreshold thermal laser coagulation with a frequency-doubled Nd:YAG continuous-wave laser","volume":"245","author":"Enders C","year":"2022","unstructured":"Enders C, Lang GE, Mayer B, Werner JU. Central serous chorioretinopathy: morphological and functional outcome after subthreshold thermal laser coagulation with a frequency-doubled Nd:YAG continuous-wave laser. Ophthalmologica. 2022, 245:59-68. 10.1159\/000519234","journal-title":"Ophthalmologica"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1186\/s12886-019-1171-5","article-title":"Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy","volume":"19","author":"Gaw\u0119cki M","year":"2019","unstructured":"Gaw\u0119cki M, Jaszczuk-Maciejewska A, Jurska-Ja\u015bko A, Kneba M, Grzybowski A. Impairment of visual acuity and retinal morphology following resolved chronic central serous chorioretinopathy. BMC Ophthalmol. 2019, 19:160. 10.1186\/s12886-019-1171-5","journal-title":"BMC Ophthalmol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/106183-a-review-of-central-serous-chorioretinopathy-clinical-presentation-and-management","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:48:09Z","timestamp":1707508089000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/106183-a-review-of-central-serous-chorioretinopathy-clinical-presentation-and-management"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,13]]},"references-count":36,"URL":"https:\/\/doi.org\/10.7759\/cureus.27965","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,8,13]]}}}